알츠하이머형 치매에서 Memantine 투여가 혈청 Total Antioxidant Capacity에 미치는 영향

참고문헌 (61)

1. Jann MW, "Cholinesterase inhibitors and similary acting compounds", pp.2808~2816 (2005), Philadelphia, Lippincott Williams & Wilkins
2. Danysz W, "The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence", 18, pp.S23~S32 (2003)
3. Flitt HM, "Achieving and maintaining cognitive vitality with aging", 77, pp.681~696 (2002)
4. Selkoe DJ, "Alzheimer disease: mechanistic understanding predicts novel therapies", 140, pp.627~638 (2004)
5. Grossberg GT, "Management of Alzheimer's disease", 58A(4), pp.331~353 (2003)
6. Ables AZ, "Memantine (Namenda) for moderate to severe Alzheimer's disease", 69, pp.1491~1492 (2004)
7. Scarpini E, "Treatment of Alzheimer's disease: current status and new perspectives", 2, pp.539~547 (2003)
8. Tanne JH, "Treatment slows moderate to severe Alzheimer's disease", 326, pp.784~ (2003)
9. Peskind ER, "Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial.", 73 (2004)
10. Wellbery CV, "Memantine for treatment of Alzheimer's disease", 70(5), pp.963~ (2004)
11. 전진숙, "알쯔하이머병의 특징과 치료", 6, pp.444~454 (2005)
12. Gauthier S, "Effects of memantine on behavioral symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies", 20, pp.459~464 (2005)
13. Winblad B, "Memantine in severe dementia: results of the M-BEST study (benefit and efficacy in severly demented patients during treatment with memantine)", 14, pp.135~146 (1999)
14. Doody R, "Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease", 18, pp.227~232 (2004)
15. Wimo A, "Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease", 21(5), pp.327~340 (2003)
16. Doody RS, "Refining treatment guidelines in Alzheimer's disease", pp.14~20 (2005)
17. Potyk D, "Treatments for Alzheimer disease.", 98, pp.628~635 (2005)
18. Farlow MR, "NMDA receptor antagonists: A new therapeutic approach for Alzheimer's disease", 59(6), pp.22~27 (2004)
19. Wenk GL, "Neuropathologic changes in Alzheimer's disease: potential targets for treatment", 67, pp.3~7 (2006)
20. Bleich S, "Glutamate and the glutamate receptor system: a target for drug action", 18, pp.S33~S40 (2003)
21. Pomara N, "Glutamate and other CSF amino acids in Alzheimer's disease", pp.251~4
22. Kornhuber J, "Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy", 41, pp.135~144 (1997)
23. Butterfield DA, "The glutamatergic system and Alzheimer's disease: therapeutic implications", 17(9), pp.641~652 (2003)
24. Milatovic D, "Carbofuran-induced oxidative stress in slow and fast skeletal muscles: prevention by memantine and atropine", 208(1), pp.13~24 (2005)
25. American Psychiatric Association, "Delium, dementia, and amnestic and other cognitive disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition", pp.123~163 (1994), Washington DC, American Psychiatric Association
26. Katzman R, "Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of health and Human services Task Force on Alzheimer's Disease", pp.939~44
27. 권용철, "의 표준화 연구-제1편 MMSE-K의 개발. 신경정신의학 1989", pp.125~35
28. 박종한, "의 표준화 연구-제2편 구분점 및 진단적 타당도. 신경정신의학 1989", 노인용 한국판 mini-mental state examination, pp.508~13
29. Hughes CP, "Martin RL. A new clinical scale for the staging of dementia. Brit J Psychiatry 1982", pp.566~72
30. Ferris SH, "Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982", pp.1136~9
31. Foy CJ, "Plasma chain-breaking antioxidants in Alzheimer's disease, vascdular dementia and Parkinson's disease", 92, pp.39~45 (1999)
32. Repetto MG, "Peripheral markers of oxidative stress in probable Alzheimer patients", 29, pp.643~649 (1999)
33. Whitehead TP, "Enhanced chemiluminescent assay for antioxidant capacity in biological fluids", 266, pp.265~77 (1992)
34. Cummings JL, "Alzheimer's disease", 351, pp.56~67 (2004)
35. Moghaddam B, "Distinct contribution of glutamate and dopamine receptors to the temporal range of rodent working memory using a task with elements of human working memory", 47, pp.62S~63S (2000)
36. zser H, "The effects of memantine on lipid peroxidation following closed-head trauma in rats", 28, pp.143~147 (2005)
37. Sobrado M, "Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation", 365(2), pp.132~136 (2004)
38. Doraiswamy PM, "Interventions for mild cognitive impairment and Alzheimer disease: New strategies, new hope", 11(2), pp.120~122 (2003)
39. Koch HJ, "NMDA-antagonism (memantine): An alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia", 10, pp.253~259 (2004)
40. Lipton SA, "Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine", 11, pp.18~20 (2004)
41. Lipton SA, "The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism", 2(2), pp.155~165 (2005)
42. Molinuevo JL, "Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias", 20(2), pp.77~85 (2005)
43. Blennow K, "Alzheimer's disease", 368, pp.387~403 (2006)
44. Sonkusare SK, "Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope", 51(1), pp.1~17 (2005)
45. Burbaeva GSh, "Glutamine synthetase from human brain: purification, properties, possible involvement in Alzheimer's disease pathogenesis", 42, pp.93S~ (1997)
46. Sobolevskii AI, "Blocker studies of the functional architecture of the NMDA receptor channel", 32(2), pp.157~171 (2002)
47. Wilcock GK, "Memantine for the treatment of dementia", 2, pp.503~505 (2003)
48. Preuss UW, "Memantine treatment in alcohol dementia: rapid PET changes and clinical course", 45(1), pp.57~58 (2001)
49. 전진숙, "치매에서 산화스트레스의 혈액지표", 7, pp.47~56 (2003)
50. 전진숙, "알쯔하이머치매 환자에서 혈청 Homocysteine 농도의 변화와 산화스트레스의 관계", 44, pp.736~742 (2005)
51. Reisberg B, "Memantine in moderate-to-severe Alzheimer's disease", 348, pp.1333~1341 (2003)
52. Tariot PN, "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial", 291(3), pp.317~324 (2004)
53. Xiong G, "Combination drug therapy for Alzheimer's disease: What is evidence-based, and what is not?", 60(6), pp.22~26 (2005)
54. Winblad B, "Memantine offers new possibilities for the treatment of VaD", 1, pp.469~ (2002)
55. Belgeri M, "A step back in time: Is there a place for older drugs in the treatment of dementia?", 59A(10), pp.1025~1028 (2004)
56. Keltner NL, "Memantine: A new approach to Alzheimer's disease", 40(3), pp.123~124 (2004)
57. Areosa SA, "Memantine for dementia", 20(3) (2005)
58. Mbius HJ, "New approaches to clnical trials in vascular dementia: memantine in small vessel disease", 13, pp.61~66 (2002)
59. Rossom R, "Efficacy and tolerability of memantine in the treatment of dementia", 2(4), pp.303~312 (2004)
60. Van Dam D, "Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model", 180, pp.177~190 (2005)
61. Davis S, "Another perspective on the memantine graphs: clinical vs. statistical significance", 88(1), pp.12~14 (2005)